Affiliation:
1. Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA
Abstract
Aim: To assess treatment patterns, healthcare resource utilization (HCRU), and costs for patients with diffuse large B-cell lymphoma (DLBCL) who did not receive stem cell transplantation in second-line. Patients & methods: An administrative MarketScan® database study to assess DLBCL claims from 01/01/2009–30/09/2020. Results: Most patients (n = 750) received rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in first-line (86.8%) and rituximab (39.5%) or bendamustine ± rituximab ± other (16.3%) in second-line. Over half were hospitalized (mean duration: 16.5 (standard deviation [SD]: 25.8) days per patient per year [PPPY]). Mean medical/pharmacy costs were US$141,532 PPPY (SD: $189,579), driven by DLBCL-related claims. Conclusion: HCRU and costs for DLBCL-related claims were due to hospitalizations and outpatient visits. Novel therapies to reduce clinical and economic burdens are needed.
Subject
Cancer Research,Oncology,General Medicine
Reference36 articles.
1. American Cancer Society. Types of B-cell lymphoma (2022). www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html
2. National Cancer Institute. SEER cancer stat facts: diffuse large B-cell lymphoma (2022). https://seer.cancer.gov/statfacts/html/dlbcl.html
3. How I manage patients with relapsed/refractory diffuse large B cell lymphoma
4. Diffuse Large B-Cell Lymphoma
5. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study